for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lee's Pharmaceutical Holdings Limited

0950.HK

Latest Trade

5.66HKD

Change

-0.07(-1.22%)

Volume

895,000

Today's Range

5.65

 - 

5.85

52 Week Range

3.45

 - 

6.82

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
5.73
Open
5.71
Volume
895,000
3M AVG Volume
33.33
Today's High
5.85
Today's Low
5.65
52 Week High
6.82
52 Week Low
3.45
Shares Out (MIL)
588.13
Market Cap (MIL)
3,369.96
Forward P/E
13.47
Dividend (Yield %)
1.01

Next Event

Lee's Pharmaceutical Holdings Ltd Annual Shareholders Meeting

Latest Developments

更多

Lee's Pharmaceutical Posts FY Profit Attributable HK$129.3 Mln Vs HK$125.6 Mln

Lee's Pharmaceutical Says Got NMPA Approval For IND Application Of GCC-4401C

Sorrento Therapeutics Says China's National Medical Products Administration Clears Lee's Pharmaceutical To Conduct Phase III Trial Of Socazolimab

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Lee's Pharmaceutical Holdings Limited

Lee’s Pharmaceutical Holdings Limited is a Hong Kong-based investment holding company principally engaged in the development, manufacture, marketing and sales of pharmaceutical products. The Company operates through two segments. Proprietary Products segment is engaged in the manufacture and sales of self-developed pharmaceutical products. Its proprietary products include Yallaferon, Livaracine and Slounase, among others. Licensed-in Products segment is engaged in the trading of licensed-in pharmaceutical products. Its licensed-in products include Ferplex and Zanidip, among others. The Company’s products are for cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology, among others. The Company mainly operates businesses in China and Hong Kong.

Industry

Major Drugs

Contact Info

Unit 110-111, Bio-Inf. Centre,

No.2 Science Park West Avenue,

Hong Kong Science Park, Shatin

Hong Kong

+852.null.23141282

http://www.leespharm.com

Executive Leadership

Siu Fong Lee

Executive Chairman of the Board

Lin Tom

President, Chief Operating Officer of CVie International Limited

Xiaoyi Li

Chief Executive Officer, Chief Technical Officer, Executive Director

Wanee Leelalertsuphakun

Managing Director, Chief Marketing & Sales Officer, Executive Director

Lit-Fui Lau

General Manager of Shanghai branch of Zhaoke

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, HKD)

2018

1.1K

2019

1.2K

2020

1.2K

2021(E)

1.4K
EPS (HKD)

2018

0.703

2019

0.212

2020

0.220

2021(E)

0.426
Price To Earnings (TTM)
20.17
Price To Sales (TTM)
2.81
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
15.68
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

港报财经评论:饮品股跑赢大市,饮得杯落--经济日报5月29日

「特金会」又话可能成行,加上油价回挫纾缓通胀预期压力,投资气氛略为改善。恒指昨收报30,792,升0.7%,国指收报12,115,升0.6%。港股交投仍然薄弱,昨日成交额只有844亿港元,如同近月香港天气,早旱!

港报财经评论:佳绩取胜,药股稳健--经济日报5月26日

「特金会」生变,港股续受压。恒指昨收报30,588点,跌0.6%,大市成交额936亿港元。国指收报12,047点,跌幅0.9%。

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up